Please ensure Javascript is enabled for purposes of website accessibility

Why XBiotech Shares Are Skyrocketing 32.7% Today

By Todd Campbell - Jan 14, 2020 at 3:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is offering to buy back shares from investors at a big premium.

What happened

After the company announced that it will repurchase up to $420 million of its shares at a price no lower than $30 nor higher than $33 apiece, shares in XBiotech (XBIT -5.71%) are surging 32.7% higher at 3:00 pm EST on Tuesday.

So what

The share repurchase follows Johnson & Johnson's (JNJ -1.86%) acquisition of XBiotech's only clinical-stage asset, bermekimab, for $750 million in December.

A man sits on the floor as dollar bills fall around him.


At the time, XBiotech said it planned to use the windfall for research that can resupply its clinical-stage pipeline and for a "capital transaction, such as a stock repurchase, subject to board review and approval." Although it was clear XBiotech was considering returning some of the proceeds to shareholders, the price it has agreed to pay appears to have caught investors off guard given yesterday's closing price of $18.62.

Shareholders can tender their shares in return for a cash payment equal to no less than $30 per share and no more than $33 per share through Feb. 12. According to management, this modified Dutch auction offer represents the best way for the company to reward investors who might want to unlock liquidity by selling shares following the disposition of bermekimab.

As you can see in the following chart, XBiotech's offer price is in line with the highest price at which XBiotech shares have traded since its IPO in 2015.

XBIT Chart

XBIT data by YCharts.

Now what

Developed using human antibodies, bermekimab is being evaluated in multibillion-dollar dermatology indications, including eczema. Initial efficacy in these indications made it incredibly attractive to Johnson & Johnson, which already markets immune-disease drugs such as Stelara and Simponi. In announcing its agreement to acquire bermekimab, J&J said, "It is the only antibody targeting IL-1a currently in clinical development and has the potential for superior efficacy and safety compared to the current standard of care" -- high praise indeed.

Perhaps J&J considered acquiring XBiotech outright; however, the price tag might have been too high. After all, XBiotech believes its human antibody platform targeting IL-1a has potential beyond dermatology in other high-value areas, including cancer and heart disease. For this reason, XBiotech included a provision in its deal allowing it to develop new therapies for nondermatological indications, and it structured its deal with J&J so that J&J will pay it up to $600 million in milestones if J&J expands bermekimab use beyond dermatology.

Regardless, XBiotech is starting over again, and that means risks. Bermekimab's purchase helps validate XBiotech's approach, but it doesn't guarantee future success. In short, the buyback offer shows management recognizes shareholders might not want to start over again, but it remains to be seen whether selling shares or sticking with management will prove to be the smarter choice in the end.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

XBiotech Inc. Stock Quote
XBiotech Inc.
$5.62 (-5.71%) $0.34
Johnson & Johnson Stock Quote
Johnson & Johnson
$175.50 (-1.86%) $-3.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.